Covalon Technologies Ltd (COV.V)
3.49
+0.10
(+2.95%)
CAD |
TSXV |
Dec 16, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 86.10M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 259.8% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.929 |
| Price to Book Value | 3.973 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 90.52% |
Profile
| Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales. |
| URL | https://www.covalon.com |
| Investor Relations URL | http://ir.covalon.com/phoenix.zhtml?c=183092&p=irol-IRHome |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Dec. 20, 2024 (est.) |
| Last Earnings Release | Aug. 21, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales. |
| URL | https://www.covalon.com |
| Investor Relations URL | http://ir.covalon.com/phoenix.zhtml?c=183092&p=irol-IRHome |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Dec. 20, 2024 (est.) |
| Last Earnings Release | Aug. 21, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |